Skip to content

Ibuprofen Versus Mecillinam for Uncomplicated Cystitis

Ibuprofen Versus Mecillinam for Uncomplicated Cystitis in Adult, Non-pregnant Women

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01849926
Acronym
IMUTI
Enrollment
383
Registered
2013-05-09
Start date
2013-04-30
Completion date
2016-07-31
Last updated
2017-11-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Cystitis (Excl in Pregnancy)

Brief summary

Although uncomplicated cystitis is considered to be a mild condition and mostly self limiting, most patients who see a doctor will be treated with antibiotics. Antibiotics are known to give a quick relief of symptoms and shorten the course of the condition by a few days. The aim of this study is to evaluate ibuprofen versus mecillinam in the treatment of uncomplicated cystitis in otherwise healthy, non-pregnant women. Our main objective is to see whether symptomatic treatment with ibuprofen is equally efficient as treatment with mecillinam in this group.

Detailed description

The design of the study will be a double blinded randomized controlled trial (RCT). Half of the patients will receive treatment with mecillinam and the other half will receive treatment with ibuprofen. The study will follow the principles of Good Clinical Practice (GCP). Urine cultures will be obtained on day one and after two weeks. The patients will be given a diary where they daily will register symptom load, possible complications or adverse effects and on which day they feel completely cured. We will contact the patients after two weeks to make sure they have followed the study procedures. After four weeks we will perform a final interview with the patient.

Interventions

DRUGIbuprofen
DRUGMecillinam

Sponsors

University of Bergen
CollaboratorOTHER
Lund University
CollaboratorOTHER
University of Copenhagen
CollaboratorOTHER
University of Oslo
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 60 Years
Healthy volunteers
Yes

Inclusion criteria

* woman between 18 and 60 years of age * dysuria and pollakiuria and/or urinary urgency * ability to give written consent

Exclusion criteria

* pregnancy/breastfeeding child under one month of age * diabetes * kidney disease * organic aciduria * clinical suspicion of pyelonephritis; fever, reduced general condition, upper back pain * vaginal symptoms such as discharge or irritation * severe abdominal pain * symptoms that have lasted for more than seven days * one or more urinary tract infections within the lasts four weeks * permanent bladder catheter or use of bladder catheter within the last four weeks * use of antibiotics within the last two weeks * participated in a clinical trial within the last four weeks * previously undergone a pyelonephritis * previous allergic reaction to penicillin * previous allergic reaction to ibuprofen, or worsening of asthma when using nonsteroidal antiinflammatory drugs(NSAIDs) * narrow oesophagus * use of the drug probenecid * severe gastritis or previous ulcer * anticoagulative treatment * ongoing use of steroids * use of immunosuppressant drugs * thrombocytopenia, * Chrohn's disease or Ulcerative colitis * heart insufficiency * severe psychiatric illness or dementia * severe drug addiction * unable to communicate in Norwegian, Swedish or Danish language

Design outcomes

Primary

MeasureTime frameDescription
Number of patients who are symptom free by day fourFour daysBoth symptom load with regard to specific symptoms and when feeling completely symptom free will be registered in the patient diary.

Secondary

MeasureTime frameDescription
The patients' symptom load with regard to specific symptoms.Seven daysSpecific symptoms, such as dysuria, urgency and pollakiuria, will be given a number from 0-6 in the patient diary, 0 = no problem and 6= as bad as it can get.

Other

MeasureTime frame
Proportion of patients who experienced severe adverse effects.Seven days
Proportion of patients who were in need of a secondary medical consult within the study period.28 days
Proportion of patients with a positive urine culture after four weeks.28 days
Proportion of patients who had a relapse of symptoms within four weeks after being included in the study.28 days
Proportion of patients who developed an upper urinary tract infection (pyelonephritis).14 days

Countries

Norway

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 18, 2026